Skip to content

Serotonin: all studies

Page 132 of 401: studies 1,311 to 1,320 of 4,004, newest first. Back to the serotonin overview

Research

Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice

Pharmacology, Biochemistry, and Behavior December 5, 2022 Youge Qu, Lijia Chang, Li Ma et al. 42 citations

Classical psychedelics with 5-hydroxytryptamine-2A receptor (5-HT2AR) agonism have rapid antidepressant actions in patients with depression. However, there is an ongoing debate over the role of 5-HT2AR in the antidepressant-like actions of psychedelics. In this study, we compared the effects of DOI (2,5-dimethoxy-4-iodoamphetamine: a hallucinogenic psychedelic drug with potent 5-HT2AR agonism),...

Psychedelic-Assisted Therapy for People with Eating Disorders.

Current Psychiatry Reports December 1, 2022 Natalie Gukasyan, Colleen C Schreyer, Roland R. Griffiths et al. 29 citations

A growing body of research suggests psychedelic-assisted therapy (PAT) may be safe and effective for a variety of mental health conditions. Among these, eating disorders have been a recent target of interest. This review provides an up-to-date summary of the potential mechanisms and use of PAT in people diagnosed with eating disorders, with a focus on anorexia nervosa. Classic psychedelics may...

4-Isobutylmethcathinone—A Novel Synthetic Cathinone with High In Vitro Cytotoxicity and Strong Receptor Binding Preference of Enantiomers

Pharmaceuticals November 30, 2022 Martin Paškan, Silvie Rimpelová, Vladimíra Svobodová Pavlíčková et al. 9 citations

New psychoactive substances and among them synthetic cathinones represent a significant threat to human health globally. However, within such a large pool of substances derived from a natural compound ((S)-cathinone), substances with important pharmaceutical uses can be identified, as already documented by bupropione. Therefore, this work aimed to find a synthetic pathway for a novel synthetic...

DOI: 10.3390/ph15121495 (opens in new tab) Serotonin Cathinone Cytotoxicity Enantiomer +7

Psilocybin in Treatment-Resistant Depression

New England Journal of Medicine November 2, 2022 Bertha K. Madras 36 citations

Depression ranks first among psychiatric disorders that dominate the global burden of disease, posing a substantial personal strain and economic drain on nations.1 At least 30 drugs are Food and Drug Administration (FDA)–approved to treat depression,2 yet a systematic review and meta-analysis of 22 antidepressants concluded that although they were more effective than placebo in adults with...

Structure–Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice

ACS Pharmacology & Translational Science November 2, 2022 Eline Pottie, Marilyn Naeem, Vamshikrishna Reddy Sammeta et al. 91 citations

4-Phosphoryloxy-N,N-dimethyltryptamine (psilocybin) is a naturally occurring tertiary amine found in many mushroom species. Psilocybin is a prodrug for 4-hydroxy-N,N-dimethyltryptamine (psilocin), which induces psychedelic effects via agonist activity at the serotonin (5-HT) 2A receptor (5-HT2A). Several other 4-position ring-substituted tryptamines are present in psilocybin-containing...

A mechanistic model of the neural entropy increase elicited by psychedelic drugs

Research Square October 26, 2022 Rubén Herzog, Pedro A. M. Mediano, Fernando E. Rosas et al. 6 citations preprint

Abstract Psychedelic drugs, including lysergic acid diethylamide (LSD) and other agonists of the serotonin 2A receptor (5HT2A-R), induce drastic changes in subjective experience, and provide a unique opportunity to study the neurobiological basis of consciousness. One of the most notable neurophysiological signatures of psychedelics, increased entropy in spontaneous neural activity, is thought...

DOI: 10.21203/rs.3.rs-2187775/v1 (opens in new tab) Serotonin Psychedelics: hallucinogens Entheogens Psychotropic drugs +16

Acute Mescaline Intoxication Followed by Catatonia

Archives of Psychiatry Research October 20, 2022 Din Duraković, Ante Silić, Vjekoslav Peitl et al. 1 citation

The paper deals with a case report of a 41-year-old man who in search of the meaning of life in a so-called “shamanic ritual” drank tea made from the San Pedro cactus as well as paste made of the same plant. The hallucinations were post poned and started after 9.5 hours caracterised by a psychotic reaction with symptoms of catatonia. He was admitted to our Department of Psychiatry where he was...

Mescaline: The forgotten psychedelic

Neuropharmacology October 14, 2022 Ian G Campbell, Ioanna A. Vamvakopoulou, Kelly A.d. Narine et al. 97 citations

The pharmacological mechanisms of mescaline are similar to those of other classical psychedelics, like psilocybin and lysergic acid diethylamide (LSD). Mescaline appears to be safe to consume, with most intoxications being mild and easily treatable. Improvement in mental well-being and its ability to overcome alcoholism render mescaline potentially beneficial in clinical settings. This article...

Ritualistic use of ayahuasca enhances a shared functional connectome identity with others

bioRxiv (Cold Spring Harbor Laboratory) October 11, 2022 Pablo Mallaroni, Natasha L. Mason, Lilian Kloft et al. 4 citations preprint

Abstract The knowledge that brain functional connectomes are both unique and reliable has enabled behaviourally relevant inferences at a subject level. However, it is unknown whether such “fingerprints” persist under altered states of consciousness. Ayahuasca is a potent serotonergic psychedelic which elicits a widespread dysregulation of functional connectivity. Used communally in religious...

The treatment of depression — searching for new ideas

Frontiers in Pharmacology October 7, 2022 Katarzyna Stachowicz, Magdalena Sowa-Kućma 48 citations

Depression is a severe mental health problem that affects people regardless of social status or education, is associated with changes in mood and behavior, and can result in a suicide attempt. Therapy of depressive disorders is based mainly on drugs discovered in the 1960s and early 1970s. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)...

DOI: 10.3389/fphar.2022.988648 (opens in new tab) Serotonin Monoaminergic Antidepressant Pharmacology +1